KarMMa-2
Phase 2 Clinical Trial Studying the Safety and Efficacy of bb2121 in Participants with Relapsed and Refractory Multiple Myeloma or Clinical High-Risk Multiple Myeloma
Filters
Save & Share
Clear Filters
Location
Explore options near your patient - or anywhere in the US.
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Near Add Your Location
Sort by
- Not currently accepting
- Show Principal Investigator
The University of Texas Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, TX
- Not currently accepting
- Show Principal Investigator
Herbert Irving Comprehensive Cancer Center (Columbia University)
Columbia University Medical Center
New York, NY
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack Meridian Health
Hackensack, NJ
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
Massachusetts General Hospital
Boston, MA
- Not currently accepting
- Show Principal Investigator
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.